Background: This study examined whether starting buprenorphine treatment prior to prison and after release from prison would be associated with better drug treatment outcomes and whether males and females responded differently to the combination of in-prison treatment and post-release service setting.
Methods: Study design was a 2 (In-Prison Treatment: Condition: Buprenorphine Treatment: vs. Counseling Only)×2 [Post-Release Service Setting Condition: Opioid Treatment: Program (OTP) vs. Community Health Center (CHC)]×2 (Gender) factorial design. The trial was conducted between September 2008 and July 2012. Follow-up assessments were completed in 2014. Participants were recruited from two Baltimore pre-release prisons (one for men and one for women). Adult pre-release prisoners who were heroin-dependent during the year prior to incarceration were eligible. Post-release assessments were conducted at 1, 3, 6, and 12-month following prison release.
Results: Participants (N=211) in the in-prison treatment condition effect had a higher mean number of days of community buprenorphine treatment compared to the condition in which participants initiated medication after release (P=0.005). However, there were no statistically significant hypothesized effects for the in-prison treatment condition in terms of: days of heroin use and crime, and opioid and cocaine positive urine screening test results (all Ps>0.14) and no statistically significant hypothesized gender effects (all Ps>0.18).
Conclusions: Although initiating buprenorphine treatment in prison compared to after-release was associated with more days receiving buprenorphine treatment in the designated community treatment program during the 12-months post-release assessment, it was not associated with superior outcomes in terms of heroin and cocaine use and criminal behavior.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5309171 | PMC |
| http://dx.doi.org/10.1016/j.drugalcdep.2016.11.037 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prescription psychostimulant use, admissions and treatment initiation and retention in pregnant people with opioid use disorder.
Nat Ment Health
July 2024
Department of Family/Community Medicine and Health and Outcomes Research, Saint Louis University School of Medicine, St. Louis, MO, USA.
While attention deficit hyperactivity disorder is common among people with addiction, the risks and benefits of attention deficit hyperactivity disorder medication in pregnant people with opioid use disorder are poorly understood. Here, using US multistate administrative data, we examined 3,247 pregnant people initiating opioid use disorder treatment, of whom 5% received psychostimulants. Compared to peers not receiving psychostimulants, the psychostimulant cohort had greater buprenorphine (adjusted relative risk 1.
View Article and Find Full Text PDFReproductive rights at the U.S. state level and medication access for pregnant women with opioid use.
Soc Sci Med
December 2024
Department of Population Health, New York University Grossman School of Medicine, New York, NY, United States.
Despite the rise in chronic, untreated opioid use among pregnant women, their rate of receiving medications for opioid use disorder (MOUD) has remained stagnant since the mid-1990s. Using retrospective cross-sectional substance use treatment admissions data from 2015 to 2019, we examined access to treatment for opioid use by pregnant adults across 48 U.S.
View Article and Find Full Text PDFEvaluating the use of sublingual sufentanil in patients with buprenorphine treatment who are undergoing ambulatory surgery: A Prospective Case Report.
Orthop Rev (Pavia)
December 2024
Anesthesiology Montefiore Medical Center, Albert Einstein College of Medicine.
Introduction: Opioid use disorder is a chronic illness with significant morbidity and mortality. Opioid agonists, like buprenorphine, are commonly used to prevent relapse. Recent changes in buprenorphine legislation are expected to increase prescription and guidelines recommend its continuation during the perioperative period for many patients.
View Article and Find Full Text PDFUnderstanding MAT access in the context of unused MAT capacity in the United States: when increasing rural MAT capacity is not enough.
Subst Abuse Treat Prev Policy
December 2024
JBS International, 11200 Rockville Pike, Suite 320, North Bethesda, MD, 20852, USA.
Background: Section 1262 Consolidated Appropriations Act of 2023 eliminates the federal DATA waiver registration requirement to prescribe buprenorphine for opioid use disorder (OUD), along with patient limits, perhaps as a way to increase provider capacity to prescribe buprenorphine. Understanding the factors that influence provider capacity, patient access, and whether community need for MAT is met could inform how to capitalize on DATA waiver eliminations in the United States.
Methods: This observational study utilized required reporting from two cohorts of the Rural Communities Opioid Response Program (RCORP).
Understanding the financial barriers to treatment among individuals with opioid use disorder: a focus group study.
Harm Reduct J
December 2024
Department of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, Health 2 Building, 4349 Martin Luther King Boulevard, Houston, TX, 77204-5047, USA.
Introduction: Despite the established effectiveness and relatively widespread availability of Medications for Opioid Use Disorder, individuals seeking treatment frequently encounter various structural and social barriers, including costs of treatment. This study aimed to understand the financial barriers that affect treatment continuation in individuals with opioid use disorder (OUD).
Methods: In this qualitative study, seven semi-structured in-depth focus group interviews were conducted among 28 participants in treatment for OUD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!